相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects
Cuiyun Li et al.
CLINICAL THERAPEUTICS (2020)
NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey
Murat Sayan et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection
Lanlan Xiao et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
How would China achieve WHO?s target of eliminating HCV by 2030?
Mingyang Li et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2019)
Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
Xiaoyuan Xu et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2019)
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Lai Wei et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study
Jia-Horng Kao et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis C genotype-4
Gamal Esmat et al.
JOURNAL OF HEPATOLOGY (2018)
Danoprevir: First Global Approval
Anthony Markham et al.
DRUGS (2018)
Current treatment status and barriers for patients with chronic HCV infection in mainland China A national multicenter cross-sectional survey in 56 hospitals
Dan-Dan Bian et al.
MEDICINE (2017)
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection A Systematic Review
Oluwaseun Falade-Nwulia et al.
ANNALS OF INTERNAL MEDICINE (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine
Amit Khatri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor
Min Zhong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors
Amit Khatri et al.
CLINICAL INFECTIOUS DISEASES (2016)
From non-A, non-B hepatitis to hepatitis C virus cure
Jean-Michel Pawlotsky et al.
JOURNAL OF HEPATOLOGY (2015)
Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir
Barbara J. Brennan et al.
CLINICAL PHARMACOKINETICS (2015)
Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients
Manish R. Sharma et al.
CLINICAL CANCER RESEARCH (2013)
Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin
Barbara J. Brennan et al.
CLINICAL PHARMACOKINETICS (2013)
Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics
Micaela B. Reddy et al.
CLINICAL PHARMACOKINETICS (2012)
Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study
Mei-Hsuan Lee et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
分享论文
